HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.

AuthorsAyalew Tefferi, Hagop Kantarjian
JournalAmerican journal of hematology (Am J Hematol) Vol. 83 Issue 3 Pg. 175-7 (Mar 2008) ISSN: 0361-8609 [Print] United States
PMID18181199 (Publication Type: Editorial)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Receptors, Platelet-Derived Growth Factor
Topics
  • Antineoplastic Agents (therapeutic use)
  • Benzamides
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, genetics)
  • Mutation
  • Piperazines (therapeutic use)
  • Protein Kinase Inhibitors (therapeutic use)
  • Pyrimidines (therapeutic use)
  • Receptors, Platelet-Derived Growth Factor (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: